| 栾微 叶寰 刘涛 江宇星 郑彰睿.利奈唑胺与万古霉素对MRSA肺炎患者血清CRP[J].现代生物医学进展英文版,2015,15(21):4060-4062. |
| 利奈唑胺与万古霉素对MRSA肺炎患者血清CRP |
| Influence of Linezolid and Vancomycin on Levels of CRP and TNF-alpha in patients with Senile Pneumonia of Methicillin-resistant Staphylococcus Aureus |
| |
| DOI： |
| 中文关键词: 耐甲氧西林金黄色葡萄球菌肺炎 老年人 利奈唑胺 万古霉素 临床疗效 炎性因子 |
| 英文关键词: MRSA pneumonia Elderly Linezolid Vancomycin Clinical effect Inflammorary factors |
| 基金项目:国家自然科学基金项目（30670935） |
|
| Hits: 784 |
| Download times: 0 |
| 中文摘要: |
| 目的：研究利奈唑胺与万古霉素治疗耐甲氧西林金黄色葡萄球菌（Methicillin-resistant , MRSA）肺炎的
临床疗效。方法：选取2010 年10 月至2013 年10 月在我院就诊的60例MRSA肺炎患者的临床资料进行分析，根据治疗方法的
不同，将所选病例分为利奈唑胺组和万古霉素组。统计并分析两组患者的临床疗效、细菌学疗效以及炎症因子水平的变化情况，
并对两种药物的安全性进行评价。结果：利奈唑胺组治疗有效率为83.33 %，致病菌清除率为86.67 %，不良反应发生率为9.52 %；
万古霉素组治疗有效率为86.67 %，致病菌清除率为84.33 %，不良反应发生率为16.00 %；但两组比较差异无统计学意义（P>0.
05）。两组患者治疗后血清中CRP、TNF-alpha 水平较治疗前明显降低，利奈唑胺组下降幅度明显高于万古霉素组，差异具有统计学意
义（P<0.05）。结论：两种药物治疗老年MRSA 肺炎的疗效差异性不大，但利奈唑胺整体优于万古霉素。 |
| 英文摘要: |
| Objective:To study the effects of linezolid and vancomycin in treatment of senile pneumonia of MRSA.Methods:Medical records of 60 senile MRSA pneumonia patients from October 2010 to 2013 in our hospital were collected and divided into linezolid
group and vancomycin group, according to different treatments. The clinical efficacy, bacteriological effect, changes of inflammation
factors, and safety evaluation of two groups were compared.Results:After a course of treatment, the effective rate of linezolid group
was 83.33 %, higher than 86.67%in the vancomycin group with no significant difference (P>0.05). The pathogen removal efficiency of
linezolid group was 86.67 %, was higher than 84.33 % in the vancomycin group with no significant difference (P>0.05). Serum CRP,
TNF-琢levels showed no significant difference between two groups of patients before treatment (P>0.05). After a course of treatment,
CRP, TNF-琢levels of two groups were significantly lower than that before treatment (P<0.05), and CRP, TNF-alpha level of linezolid group
were decreased significantly than that in vancomycin group (P<0.05). The adverse reaction incidence rate of linezolid group was 9.52 %,
was lower than 16 %in vancomycin group, but no significant difference between the two groups (P>0.05).Conclusion:The cu- rative
effect of linezolid and vancomycin in the treatment of elderly MRSA pneumonia is similar, but overall linezolid is better than vancomycin. |
|
View Full Text
View/Add Comment Download reader |
| Close |
